Monopar Therapeutics (MNPR) Return on Assets (2018 - 2020)

Monopar Therapeutics' Return on Assets history spans 3 years, with the latest figure at 0.35% for Q3 2020.

  • For Q3 2020, Return on Assets rose 40.0% year-over-year to 0.35%; the TTM value through Sep 2020 reached 0.35%, up 40.0%, while the annual FY2019 figure was 0.42%, 4.0% down from the prior year.
  • Return on Assets for Q3 2020 was 0.35% at Monopar Therapeutics, up from 0.36% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.31% in Q1 2020 and bottomed at 1.96% in Q2 2018.
  • The 3-year median for Return on Assets is 0.47% (2019), against an average of 0.73%.
  • The largest YoY upside for Return on Assets was 127bps in 2019 against a maximum downside of -37bps in 2019.
  • A 3-year view of Return on Assets shows it stood at 0.44% in 2018, then fell by -7bps to 0.47% in 2019, then rose by 25bps to 0.35% in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Return on Assets are 0.35% (Q3 2020), 0.36% (Q2 2020), and 0.31% (Q1 2020).